Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica Makofske"'
Autor:
Anhthu Dang, Deborah Knee, Cui Ying Wang, Feng Gao, Guoxun Liu, Sergio Briones, Michelle Coulson, Jessica Makofske, Keith Mansfield, May Liu, Tanya Mulvey, Emily K Meseck, Steve Woolfenden, Sean G Buchanan, David Steensma, Vasileios Askoxylakis
Publikováno v:
Blood. 140:11564-11565
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d3e920fadb2ab0859e7a27380e4191b
https://doi.org/10.1182/blood-2022-159910
https://doi.org/10.1182/blood-2022-159910
Autor:
Norbert Vey, Sebastian Scholl, Anisa Mohammed, Purushotham Naidu, Fei Ma, Uma Borate, Andrew M. Brunner, Nidhi Patei, Mika Kontro, Jeroen Janssen, Elena Orlando, Elie Traer, Martin Wermke, Natalia Tovar, Steve Knapper, Jessica Makofske, Mikael L. Rinne, Oliver G. Ottmann, Rupa Narayan, Andrew H. Wei, Guillermo Garcia-Manero, Sun Loo, Na Zhang, Kimmo Porkka
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S350
Context: Sabatolimab (MBG453) is an investigational immuno-myeloid therapy targeting TIM-3, an immune regulator expressed on immune and myeloid leukemic cells and blasts, but not on normal hematopoietic stem cells. Early phase 1b study (NCT03066648)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a25703819b83ebb1e0b2875cd3accd9e
https://doi.org/10.1016/s2152-2650(21)01811-5
https://doi.org/10.1016/s2152-2650(21)01811-5
Autor:
Guillermo Garcia-Manero, Andrew H. Wei, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Natalia Tovar, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Elena Orlando, Nidhi Patel, Jessica Makofske, Fei Ma, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew M. Brunner
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S230
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d02830f5143edc76e3e23bfdc52be262
https://doi.org/10.1016/s2152-2650(21)01447-6
https://doi.org/10.1016/s2152-2650(21)01447-6
Autor:
Catherine Anne Sabatos-Peyton, Serena Liao, Oliver G. Ottmann, Guillermo Garcia-Manero, Jordi Esteve, Sun Loo, Elie Traer, Natalia Tovar, Anisa Mohammed, Jessica Makofske, Rupa Narayan, Mika Kontro, Uma Borate, Andrew H. Wei, Norbert Vey, Purushotham Naidu, Mikael L. Rinne, Steve Knapper, Sebastian Scholl, Sema Kurtulus, Jeroen Janssen, Kimmo Porkka, Andrew M. Brunner, Martin Wermke
Publikováno v:
Blood. 136:1-2
Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. TIM-3 is expressed on immune cells as well as leukemic stem cells (LSCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::587f65d983f09fdb9db1677116138862
https://doi.org/10.1182/blood-2020-136855
https://doi.org/10.1182/blood-2020-136855